Michael Marks
Angel Investor @ Celesta Capital
Menlo Park, United States
Michael Marks is a Series A investor at Celesta Capital in Menlo Park focused on Internet and Software. Michael E Marks is the Founding Managing Partner at Celesta Capital. Prior to that, he was the CEO and founder of Katerra. He was also the founding partner of Riverwood Capital, a Menlo Park-based private equity firm. Prior to establishing Riverwood, he was a partner and senior advisor at Kohlberg Kravis Roberts & Co. in 2006 and 2007.Priorto KKR, Michael spent 13 years as CEO and then chairman of Flextronics International Ltd., building it into one of the largest technology companies in the world.He is a director of The Melt, Enjoy, H20.ai, and Berkeley Lights.
- Total investments:
- 42
- Last investment:
- Lead investor:
- 57%
Last updated:
For AI agents: llms.txt
Industries Michael Marks invests in
Stages Michael Marks invests in
Countries Michael Marks invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $850k–$13M
- Series A
- $3M–$16M
- Series B
- $1.7M–$27M
Investment Focus
Industry
- Internet 5 (12%)
- Software 5 (12%)
- E-Commerce 5 (12%)
- Analytics 4 (10%)
- Artificial Intelligence 4 (10%)
Stage
- Series A 10 (24%)
- Seed 8 (19%)
- Series B 3 (7%)
- Series C 3 (7%)
- Convertible Note 2 (5%)
Country
- United States 19 (45%)
- India 2 (5%)
- Japan 1 (2%)
- Brazil 1 (2%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| OneCell Diagnostics is a Precision Oncology Liquid Biopsy Diagnostics Company. | $16M / Series A / Nov 21, 2024 | ||
| Finicast provides business financial planning and analysis software. Finicast software assists FP&A teams, financial analysts, and businesses in developing detailed and scalable financial forecasts, as well as financial management and tracking solutions. | $12.8M / Seed / Jul 27, 2023 | ||
| Very Good Ventures is an design and development firm dedicated to enabling software excellence on any platform. We are the world leaders in Flutter development. We collaborate with global scale enterprises and emerging startups to create, build, and scale successful apps. We unite technology, empower teams, and amplify experiences. | $3.4M / Series A / Jul 26, 2023 | ||
| Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics' technology leverages massive gains in print speed and resolution to break the microvasculature barrier.The companywas founded in 2016 and is based in San Francisco, California. | $35M / Series C / Aug 10, 2022 | ||
| Very Good Ventures is an design and development firm dedicated to enabling software excellence on any platform. We are the world leaders in Flutter development. We collaborate with global scale enterprises and emerging startups to create, build, and scale successful apps. We unite technology, empower teams, and amplify experiences. | $3M / Series A / May 17, 2022 | ||
| Biomason is a developer of a building materials technology to produce biological cement-based building materials alternatives. Its bio cement production combines natural microorganisms and chemical processes to develop masonry materials at room temperature, which helps replace traditional clay and concrete, and the high energy consumptionassociated with standard manufacturing them, enabling builders to acquire alternative building materials that are produced carbon-free.Since 2012, the company has used microorganisms to grow sustainable, structural biocement® in ambient temperatures, harnessing the power of biotechnology to reinvent traditional cement and offer a planet-friendly alternative. Biocement will eliminate 25% of the concrete industry’s global carbon emissions by 2030. Biomason bio cement is in use in projects throughout the US and Europe, and bioLITH precast tile products are commercially available. | $65M / Series C / Feb 28, 2022 | ||
| We’re on a mission to transform eCommerce – end-to-end – starting with fresh groceries and other home essentials. Powered by the latest in AI and advanced robotics, our patented automated fulfillment system, RoboFS, enables quick, touchless order fulfillment, bringing fresher-than-store goods, direct to your door. Our shopping experience isalso built around each customer’s dietary needs, preferences, and brand favorites. Gone are the days of filtering and scrolling through irrelevant inventory. With HDS, you’ll only ever see products that match your exact criteria. HDS also offers: • Made-to-order meats and prepared foods, customized to your exact specs • Free home delivery with no subscription /delivery / service fees or tips • Tri-temperature-controlled vans, so frozen items arrive fully frozen • Retail-level customer service and easy at-home returns, right at your doorstep • Sustainable delivery totes, eliminating nearly all cardboard and plastic waste | $5M / Jan 14, 2022 | ||
| Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics' technology leverages massive gains in print speed and resolution to break the microvasculature barrier.The companywas founded in 2016 and is based in San Francisco, California. | $14.5M / Series B / Dec 15, 2021 | ||
| Rizzle is a short video platform bringing unique formats and simplifying high-quality video creation using AI-based camera experiences. Rizzle is one of the top platforms for original content. With video responses, Rizzle enables a positive creator community. Rizzle supports sponsorships for creators, making it an integrated platform for creation,distribution, and monetization. | $17M / Convertible Note / Sep 16, 2021 | ||
| Rizzle is an AI video creation platform. Rizzle works with Media and Publishers to transform their written content (articles, stories, newsletters and blogs) into engaging videos. Rizzle then helps its media and publishing customers distribute their content onto media and social platforms, as well as on their own sites and other video distributionnetworks. Finally, Rizzle drives the monetization of those videos as well as the measurement and analytics to determine what is working best and what is not yet working. | $17M / Convertible Note / Sep 16, 2021 | ||
| See all 42 investments → | |||
Co-Investors
About Celesta Capital
Celesta Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Skip Glass
Venture Partner
|
|||
Steve Fu
Partner
|
|||
David Goldman
Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Michael Marks invest in?
Michael Marks invests primarily in Internet, Software and E-Commerce startups, most often at Series A and Seed stage. Most of the 42 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Michael Marks's check size?
Michael Marks typically joins rounds of $850k–$13M at Seed, $3M–$16M at Series A and $1.7M–$27M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Michael Marks participates in.
How do I contact Michael Marks?
Public channels for Michael Marks include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Michael Marks last invest?
The most recent investment recorded for Michael Marks closed in Nov 2024. Shizune tracks 42 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
